














































id Activates Multiple Mitochondrial Apoptotic Mechanisms in
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actor receptor 1 (TNF-R1) on hepatocytes leads to
poptosis, which requires mitochondria activation. The
ro-death Bcl-2 family protein, Bid, mediates this path-
ay by inducing mitochondrial releases of cytochrome c
nd other apoptotic factors. How Bid activates mito-
hondria has been studied in vitro with isolated mito-
hondria. We intended to study the mechanisms in in-
act hepatocytes so that findings could be made in a
roper cellular context and would be more physiologi-
ally relevant. Methods: Hepatocytes were isolated from
ild-type and bid-deficient mice and treated with anti-
as or TNF-. Mechanisms of mitochondria activation
ere dissected with genetic, biochemical, and morpho-
ogic approaches. Results: bid-deficient hepatocytes
ere much more resistant to apoptosis. Bid was re-
uired for permeability transition and mitochondria de-
olarization in addition to the previously defined release
f cytochrome c. Permeability transition inhibitors cyclo-
porin A and aristolochic acid could inhibit mitochondria
ctivation effectively, but not as much as the deletion of
he bid gene, and they could not inhibit Bak oligomer-
zation. In addition, mitochondria depolarization also
ould be induced by caspases, whose activation was
ainly dependent on Bid. Conclusions: Bid may activate
itochondria by 2 mechanisms, one is related to per-
eability transition and the other is related to Bak
ligomerization. Bid can further affect mitochondria po-
entials by indirectly regulating caspase activity. This in
ivo study provides novel findings not previously dis-
losed by in vitro studies, and indicates the importance
f several mechanisms in contributing Bid-mediated mi-
ochondria dysfunction that could be potential cellular
argets of intervention.
epatocyte apoptosis induced by the activation of
the death receptor Fas or tumor necrosis factor
eceptor 1 (TNF-R1) may account for the pathogenesis of
number of liver diseases.1–3 Both in vitro and in vivo
odels have been established to study the apoptosis
echanisms. Fas can be activated by anti-Fas antibodies,
nd TNF-R1 can be activated by TNF- or TNF-nducers, such as lipopolysaccharide, in the in vivo mod-
ls.4–9 In both models, caspases are activated and critical
o hepatocyte apoptosis, which can be suppressed by
aspase inhibitors.6,8–11
A significant phenomenon observed in the in vivo
tudies is the need for mitochondrial activation for the
fficient execution of the death program. Deletion of Bid,
pro-death Bcl-2 family molecule functioning on the
itochondria, can render hepatocytes resistant to
eath.12,13 Bid can be activated proteolytically by
aspase-8 after death receptor activation and the trun-
ated Bid is translocated to the mitochondria to induce
ytochrome c and Smac release,12–14 which are important
or effective caspase activation and for the progression of
he death program.
The mechanism of these Bid-mediated mitochondrial
vents is not understood completely. In vitro studies
onducted with isolated mitochondria indicate that Bid
oes not cause mitochondrial swelling, permeability
ransition, and mitochondria depolarization.15–19 How-
ver, whether this is the case in cells is not known. From
his point, it was reported that cyclosporin A (CsA), by
tself or in combination with trifluoperazine, could block
ytochrome c release in cultured hepatocytes stimulated
ith anti-Fas or TNF-.8,9 CsA is an inhibitor of mito-
hondrial permeability transition (PT) pore, which in-
eracts with mitochondria cyclophillin D,20 and whose
ffects could be enhanced significantly by trifluoperazine
r aristolochic acid (Ara).9,21–23 Thus, these studies sug-
est that PT may be important for cytochrome c release
n hepatocytes after death receptor engagement. When
he in vivo data are taken into consideration, these
Abbreviations used in this paper: ActD, Actinomycin D; Ara, aristolo-
hic acid; CsA, cyclosporin A; CHX, cycloheximide; MTT, 3 (-4,5-di-
ethylthiazol-2-yl)2, 5-diphenyltetrazolium bromide; PT, permeability
ransition; TMRM, tetramethyrhodamine methyl ester; TNF-R1, tumor
ecrosis factor receptor 1.





































studies would also suggest that Bid may induce cyto-
chrome c release by affecting permeability transition.
The current study was performed to address how Bid
activates the mitochondria in cells in terms of its rela-
tionship with permeability transition, CsA, and caspases.
We found that in a hepatocyte culture system, in which
bid-deficient hepatocytes were much more resistant to
TNF-– or anti-Fas–induced apoptosis, mitochondria
activation was also deficient in these cells, including
permeability transition, mitochondria depolarization,
and cytochrome c release. The PT inhibitor, CsA, in
combination with Ara, suppressed depolarization and
cytochrome c release in wild-type cells to an extent close
to, but not equivalent to, that caused by bid deficiency.
These data support the notion that Bid may activate
mitochondria apoptosis machinery through both a CsA-
sensitive and a CsA-insensitive mechanism. The latter is
likely related to Bak oligomerization because it could not
be suppressed by the chemicals. In addition, mitochon-
dria depolarization, but not cytochrome c release, could
also be caused by the feedback effects of downstream
effector caspases. Taken together, these data indicated
that the effect of Bid on mitochondria, including per-
meability transition, cytochrome c release, and mitochon-
dria depolarization, can be mediated by multiple mech-
anisms based on their sensitivities to inhibitors of
permeability transition and caspases.
Materials and Methods
Mice
Mice deficient in bid were established by gene target-
ing and had been back-crossed to the C57BL/6 background for
12 generations.12,13 Wild-type and bid-deficient mice used in
this study were littermates and weighed about 25–30 g. They
were maintained as homozygotes in a specific pathogen-free
facility on the campus in compliance with the National Insti-
tutes of Health and University of Pittsburgh policies.
Establishment of Primary Hepatocyte
Culture
Murine hepatocytes were isolated using the collagenase
digestion method as previously described.24–26 Cells were cul-
tured in William’s medium E with all standard supplements
on Falcon Primaria 24-well plates (Falcon 3847; Becton-Dick-
inson, Franklin Lakes, NJ) at a density of 8  104 cells/well for
cell viability analysis and immunostaining, or 5  106 cells/
100-mm collagen-coated dishes for Western blot and caspase
activity assays. Cells were allowed to attach to the plate for 2–3
hours or overnight, before they were washed again with me-
dium and treated with various chemicals as indicated in all the
figure legends.
Determination of Cell Viability and
Apoptosis
Cell viability was determined mainly by the following
2 methods. The tetrazolium salt method used (3,4.5-dimeth-
ylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) and
examined its conversion to colored formazan as a way to
measure cell growth and viability. This assay was performed
essentially as described previously.27 Alternatively, cells were
first fixed with 4% paraformaldehyde and then stained with
Hoechst 33342 (5 g/mL). Apoptotic cells showing nuclear
condensation and/or fragmentation were quantified by digital
microscopy.
Detection of Permeability Transition and
Mitochondrial Depolarization by Confocal
and Conventional Fluorescence Microscopy
Cell culture and confocal microscopy were per-
formed essentially as described previously.8,9,28 Briefly,
hepatocytes were plated in a 4-well chamber (Nunc, Na-
perville, IL) at 1  105 cells/well and cultured at 37°C. At
the designated time points after treatment, cells were
loaded with 0.5 mol/L of TMRM (Molecular Probes,
Eugene, OR) for 15 minutes, followed by 1 mol/L of
Calcein AM (Molecular Probes) for another 15 minutes.8,9,28
Cells were then monitored on a heating stage (37°C) of a
laser scanning confocal microscope (Leica, Bannockburn,
IL). For the conventional fluorescence microscopy study,
hepatocytes were plated in a 24-well plate (Falcone 3847) at
1  105 cells/well, stimulated and then loaded with 0.5
mol/L of TMRM for 15 minutes at 37°C before being
examined by digital microscopy.
Analysis of Cytochrome c Release
Immunostaining essentially was performed as de-
scribed previously.29 Briefly, hepatocytes in the 24-well plates
were fixed in 4% paraformaldehyde and permeabilized with
0.4% Triton X-100 with 10% normal goat serum. Cells were
then stained with an anti-cytochrome c antibody (clone
6H2.B4; BD PharMingen, San Diego, CA; 1:500) followed by
Cy3-conjugated goat anti-mouse antibody (1 g/mL; Jackson
Immunoresearch, West Grove, PA). Cells were counterstained
with Hoechst 33342 (5 g/mL) before digital microscopy was
conducted. Western blot analysis was conducted as previously
described.30–32 Cells were harvested, washed, and then treated
with 0.05% digitonin in isotonic buffer A (10 mmol/L
HEPES, 150 mmol/L NaCl, 1.5 mmol/L MgCl2 , 1 mmol/L
ethylene glycol-bis(-aminoethyl ether)-N,N,N,N-tetraace-
tic acid, pH 7.4) containing a cocktail of protease inhibitors for
2 minutes at room temperature. Cells were centrifuged at
10,000 rpm for 10 minutes and the supernatants (digitonin-
released cytosol) were analyzed by Western blot for the mito-
chondria-released cytochrome c and other cytosol proteins,
such as 14-3-3.
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Bak Cross-Linking
This was conducted as previously described.30,32 Essen-
tially, cells were harvested, washed, and first permeabilized
with 0.05% digitonin in isotonic buffer A at room tempera-
ture for 2 minutes as described earlier. After centrifugation at
5000 rpm for 10 minutes at 4°C, the pellet was extracted
further with ice-cold lysis buffer (2% CHAPS in buffer A
containing protease inhibitors) for 60 minutes at 4°C to obtain
the membrane fraction. The membranes extracted with
CHAPS were incubated with 1 mmol/L Dithiobis succinimi-
dylpropionate (Pierce, Rockford, IL) or the solvent, dimethyl
sulfoxide, on a nutator for 30 minutes at room temperature,
followed by separation on a 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blot with an anti-Bak antibody (Upstate Biotechnology, Lake
Placid, NY).
Analysis of Caspase Activities
At a designated time point, hepatocytes were scraped
off the plates, washed, and resuspended in buffer B (150
mmol/L NaCl, 20 mmol/L Tris. pH 7.2, 1 mmol/L dithio-
threitol, 1% Triton X-100, or NP-40 with a cocktail of
protease inhibitors). After 3 cycles of freezing and thawing, the
lysates were cleared by centrifugation. Caspase activities were
measured by incubating 20 g of proteins with 25 mol/L of
fluorescent substrates in an analysis buffer (20 mmol/L KCl, 20
mmol/L Pipes pH 7.4, 4 mmol/L MgCl2 , 2 mmol/L dithio-
threitol) at 37°C for 30–60 minutes. The fluorescence signals
were determined by a fluorescence spectrometer (LS 50B;
Perkin Elmer, Wellesley, MA) at 400 nm/505 nm (excitation/
emission).
Results
Hepatocytes Deficient in bid Are Refractory
to Anti-Fas or TNF-
To study the mechanism by which Bid activates
the mitochondria in the cell, we had set up a primary
hepatocyte culture and verified the role of Bid in anti-
Fas– or TNF-–induced apoptosis in this system. Cell
viability was monitored at different times after the treat-
ment by MTT assay (Figure 1A ), nuclear staining (Fig-
ure 1B), trypan blue staining, and visual inspection by
phase microscopy (data not shown). Data from all these
assays were comparable and showed that a majority of
wild-type hepatocytes were killed by anti-Fas or TNF-
in the presence of cycloheximide (CHX) or actinomycin
D (ActD) within 24 hours (Figure 1A ). Nuclear frag-
mentation and condensation could be observed easily
(Figure 1B). Although anti-Fas–induced killing pro-
gressed more quickly than that induced by TNF-, in
either treatment hepatocytes deficient in bid were signif-
icantly more resistant than the wild-type cells as deter-
mined by all the criteria. The difference between wild-
type and bid-deficient cells was not in the rate of viability
loss, but seemed to be in the time when death became
noticeable. The kinetics indicated that bid-deficient cells
had a lag of 6–8 hours to progress through the death
program. Thus, the data suggest that the role of Bid is to
engage a mechanism that allows an early activation of the
death program in this cultured system. Also, in this
system anti-Fas or TNF- alone could not kill the he-
patocyte owing to the activation of nuclear factor B,5,7,9
whose effects, however, could be suppressed by either
ActD or CHX. These chemicals alone had no effects on
cell viability at the dose used in the time frame analyzed
(data not shown). Blocking nuclear factor B activation
with a nondegradable dominant-negative I-B mutant9
resulted in similar findings (data not shown).
Engagement of Fas or TNF-R1 by the agonistic anti-
body Jo-2 or the ligand TNF-, respectively, can lead to
the activation of an initiator caspase, caspase-8, and
effector caspases.33 Consistent with the viability analysis,
both types of caspases were activated earlier in anti-Fas–
treated hepatocytes than in TNF-–treated cells (Figure
1C ). However, in both cases, activation of these caspases
was delayed significantly in time and reduced in magni-
tude in bid-deficient hepatocytes either by enzymatic
activity measurement (Figure 1C ) or by Western blot for
caspase-3 or caspase-3 substrate cleavage (data not
shown). The higher caspase-8 activity in the wild-type
hepatocytes was likely due to the higher caspase-3 activ-
ity, which could engage in a feedback amplification of
pro– caspase-8 processing.14,34 There is no defect in
caspase-8 activation in bid-deficient hepatocytes.14 At the
later time point, the difference in the caspase activities
between the 2 types of hepatocytes treated with TNF-
/ActD became smaller, indicating that additional Bid-
independent mechanisms were activated by then.13
These data confirmed and extended previous findings
from animal studies, showing the dominant role of Bid
in death receptor–mediated hepatocyte apoptosis. Fur-
thermore, it indicated that the culture system was ade-
quate to address the mechanism by which Bid induces
mitochondria damage.
Bid-Dependent Cytochrome c Release Is
Accompanied With Mitochondria
Permeability Transition and Mitochondria
Depolarization
The Bid-dependent pathway is mediated by mi-
tochondria and is a more potent mechanism for caspase-3
activation through the apoptosome.12,13,35 Indeed Bid
was cleaved in wild-type hepatocytes after Fas/TNF-R1
engagement (Figure 2A ). Correspondingly, cytochrome c
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Figure 1. bid-deficient hepatocytes are refractory to TNF- or anti-Fas antibody treatment. (A) Hepatocytes were prepared from (●) wild-type and
(E) bid-deficient mice and treated with TNF- (10 ng/mL, Sigma) (a) or anti-Fas (0.5 g/mL, BD PharMingen, clone Jo-2) (b) in the presence of
ActD (50 ng/mL) or CHX (10 g/mL), respectively. Viabilities were determined at designated time points by MTT assay and standardized to
nontreated controls (mean  SD). (B) Representative micrographs of Hoechst 33342 nuclear staining of (a–c) wild-type or (d–f) bid-deficient
hepatocytes cultured for 8 hours in the (a, d) absence or the (b, e) presence of TNF-/ActD or (c, f) anti-Fas/CHX. Arrows indicate fragmented
or condensed nuclei. (C) Activities of (a, b) caspase-8 and (c, d) caspase-3 in ( ) wild-type or () bid-deficient hepatocytes treated with (a, c)
TNF-/ActD or (b, d) anti-Fas/CHX for 4, 10, or 16 hours were measured using Ac-IETD-AFC or Ac-DEVD-AFC, respectively. The activities were
represented as fold-increase of nontreated controls (mean  SD). ActD or CHX alone did not cause cell death more significantly than controls
without treatment or with vehicle only (data not shown). For A and C, a t test was conducted between the wild-type and bid-deficient groups (*P 
0.05; **P  0.01).
was released as determined by immunofluorescence mi-
croscopy (Figure 2B). Staining of the hepatocyte with an
anti– cytochrome c antibody could clearly define cells
with mitochondrial or cytoplasmic localization of the
protein. We only evaluated cells with intact morphology
to focus on changes at the early stage based on the
kinetics of viability and caspase activation, and avoided
the inclusion of apparently dead cells that might have
altered cytochrome c staining owing to nonspecific later
events. Under the current regimen, the percentage of
wild-type cells with a cytoplasmic distribution of cyto-
chrome c increased dramatically after anti-Fas or TNF-
treatment. In contrast, cytochrome c release was minimal
in bid-deficient hepatocytes after the same treatment
(Figure 2C ). The differences between the wild-type and
the bid-deficient groups were statistically significant.
These results also were confirmed by Western blot anal-
ysis (see below in Figure 5).
Figure 2. Bid is activated in
hepatocytes treated with TNF-
or anti-Fas and is responsible
for cytochrome c release. (A)
Bid cleavage in wild-type hepa-
tocytes cultured with TNF-/
ActD or anti-Fas/CHX for 4 or 8
hours. Whole-cell lysates were
prepared and subjected to
SDS-PAGE followed by Western
blot with an anti-Bid antibody.
Cleaved Bid could be detected
in anti-Fas–treated cells as
early as 4 hours after treat-
ment, but became apparent in
TNF-–treated cells at 8 hours
as well. *Nonspecific band. (B)
Cytochrome c release in (a–c)
wild-type or (d–f) bid-deficient
hepatocytes after treatment
with (b, e) TNF-, (c, f) anti-Fas,
or (a, d) vehicle control for 8
hours. Cells were immuno-
stained with an anticytochrome
c antibody and counterstained
with Hoechst 33324. Arrows in-
dicate cells with typical cyto-
plasmic distribution of cyto-
chrome c. (C) Quantification of
cells with cytochrome c release
in ( ) wild-type and () bid-de-
ficient hepatocytes treated with
TNF- or anti-Fas for 4 or 8
hours. Cells with cytoplasmic
distribution of cytochrome c
were recorded and quantified
with a fluorescence micro-
scope. The numbers were ex-
pressed as the percentage of
total cells with cytochrome c
staining (mean  SD). A t test
was performed between wild-
type and bid-deficient groups
(**P  0.01).
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A key issue in the activation of the mitochondrial
pathway is how cytochrome c is released. Several mech-
anisms involving the mitochondrial permeability transi-
tion have been proposed.22,35–37 Inhibitors of PT, such as
CsA, have been shown to be effective in blocking anti-
Fas– or TNF-–induced hepatocyte death in culture.8,9
Because Bid played a significant role in this type of death
by inducing cytochrome c release, we examined whether
Bid could be involved in the induction of PT in cultured
hepatocytes. If so, PT would be reduced in bid-deficient
hepatocytes after the treatment.
To accomplish this, we adopted an imaging method
that monitors the distribution of a fluorescence probe,
Calcein AM, across the mitochondria. Under normal
conditions, the mitochondrial inner membrane is imper-
meable to Calcein AM and thus this green fluorescence
dye is distributed exclusively in the cytosol.8,9,28,38 Re-
distribution of Calcein AM from the cytosol to the
mitochondria signifies the onset of mitochondrial perme-
ability transition.8,9,28,38 Calcein AM redistribution into
the mitochondria could be observed around 3 hours after
anti-Fas treatment and around 8 hours after TNF-
treatment in wild-type hepatocytes (Figure 3). CsA was
able to block the altered distribution of Calcein AM (data
not shown).8,9,28,38 In contrast, bid-deficient hepatocytes
showed unchanged Calcein AM distribution in the same
time frame (Figure 3). Thus, the data indicated that
anti-Fas– and TNF-–induced permeability transition,
as defined by this technique, could be caused in large
part by the effects of Bid.
We also found that significant depolarization in the
wild-type hepatocytes occurred in association with the Cal-
cein AM redistribution (Figure 3). However, bid-deficient
cells seemed to be able to maintain their mitochondrial
transmembrane potentials (Figure 3). The change in trans-
membrane potentials was thus parallel to that in Calcein
AM redistribution (Figure 3). To gain an understanding of
these changes across the population (Figure 4A), we quan-
tified the number of depolarized cells, which indicated that
a significantly greater amount of wild-type hepatocytes than
bid-deficient cells failed to maintain the mitochondrial po-
tentials after the treatment (Figure 4B).
Taken together, it seems that the effects of Bid on
mitochondrial permeability transition and transmem-
brane potentials were parallel to its effects on mitochon-
drial cytochrome c release. These results further sug-
gested that there could be mechanistic relationships
among these events.
Figure 3. Anti-Fas or TNF- in-
duces mitochondrial permeabil-
ity transition and depolarization
in wild-type but not in bid-defi-
cient hepatocytes. Wild-type





treated with (A) TNF-/ActD or
(B) anti-Fas/CHX for 6 or 0.5
hours, respectively. Cells were
then loaded with 0.5 mol/L of
tetramethylrhodamine methyl
ester (TMRM) for 15 minutes,
followed by 1 mol/L of Cal-
cein AM for another 15 min-
utes. The plates were then
mounted onto the heating
stage (37°C) of a laser scan-
ning confocal microscope
(Leica). The cells were exam-
ined in the next several hours.
Representative micrographs of
Calcein AM and TMRM staining
are shown for cells treated with
(A) TNF-/ActD for a total of 7
or 9 hours and for (B) cells
treated with anti-Fas/CHX for 1
or 4 hours as indicated.
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Figure 4. bid-deficient hepatocytes are resistant to anti-Fas–or TNF-–induced mitochondrial depolarization. (A) (a–c, a–c) Wild-type and (d–f,
d–f) bid-deficient hepatocytes were treated with (a, a, d, d) vehicle control, (b, b, e, e) TNF-/ActD, or (c, c, f, f ) anti-Fas/CHX. Eight hours
later, TMRM (0.5 mol/L) was added for 30 minutes. Cells were counterstained with Hoechst 33324 and then observed under a fluorescence
microscope. Representative fields were first selected under (a–f ) phase contrast and then the (a–f ) TMRM and Hoechst signals of the cells
were recorded with a digital camera. Many depolarized cells showed apoptotic morphology with fragmented nuclei and rounded cell shape
(arrows), although some still kept normal morphology (arrowheads). A significantly greater number of bid-deficient hepatocytes maintained normal
potentials and morphology. (B) Depolarized ( ) wild-type or () bid-deficient cells after TNF- or anti-Fas treatment for 4 or 8 hours were quantified
and the number was expressed as the percentage of total cells (polarized and depolarized, based on phase-contrast observation) (mean  SD).
The difference between wild-type and bid-deficient groups was significant (*P  0.05; **P  0.01).
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Bid Could Activate Multiple Mechanisms to
Induce Cytochrome c Release and
Mitochondria Depolarization
To investigate these relationships, we used PT
inhibitors and compared their effects with those of bid
deficiency on the mitochondrial events induced by the
death receptor activation. Wild-type and bid-deficient
hepatocytes were treated as described earlier, but in the
presence of CsA together with Ara. The quantitative data
indicated that CsA/Ara could suppress TNF-– or anti-
Fas–induced cytochrome c (Figure 5A–D). The percent-
age of cells that did release cytochrome c was reduced to
a level close to that of similarly treated bid-deficient cells,
but in the absence of CsA/Ara (Figure 5A, B). This was
confirmed by immunoblot analysis, which indicated cy-
tochrome c release only in wild-type but not bid-deficient
treated cells and that CsA/Ara effectively, but not com-
pletely, suppressed the process (Figures 5C, D). In par-
allel, CsA/Ara could also efficiently reduce the number of
depolarized wild-type cells after the treatment, although
again not to the same level observed in equivalently
treated bid-deficient cells without CsA/Ara (Figure 6).
Thus, it seemed that cytochrome c release and mitochon-
dria depolarization could be mediated mainly through a
Bid-dependent, CsA-sensitive mechanism. However, be-
cause bid-deficiency consistently resulted in less cyto-
chrome c release (by both immunostaining and immu-
noblotting analyses) and a better protection against
Figure 5. Differential effects of PT and caspase inhibitors on cytochrome c release. ( ) Wild-type or () bid-deficient hepatocytes were treated
with (A, C, D) TNF-/ActD or (B–D) anti-Fas/CHX for 8 hours. CsA (10 mol/L) plus Ara (50 mol/L), z-VAD-fmk (50 mol/L), or DEVD-CHO (50
mol/L) was added at the beginning of the culture in selected groups as indicated. Controls were vehicle only. At the end of the culture, 2 assays
were performed for cytochrome c release. (A, B) Cells were fixed and immunostained for cytochrome c as shown in Figure 2. Cells with
cytoplasmic distribution of cytochrome c were quantified and the numbers were expressed as the percentage of the total cells with cytochrome
c staining (mean  SD). (C) Alternatively, treated cells were processed with digitonin and the released cytosolic fractions were analyzed by
SDS-PAGE and immunoblotted with anti–cytochrome c or anti-14-3-3 antibody (for loading control of bid-deficient samples). Asterisk in the
anti–cytochrome c blot of wild-type samples indicates a cross-reactive product, which serves as a spurious loading control for these samples.
(D) Densitometry was conducted on blots as represented in panel C and fold-increase of the density over the control treatment was determined
(mean  SD from 3 experiments). All statistical analyses were performed with a t test. (A, B) Comparisons were made between (A) TNF-– or
(B) anti-Fas–treated groups and other treatment groups for wild-type hepatocytes except for the pairs indicated by ‡. (D) Comparisons were made
between TNF-– or anti-Fas–treated groups alone and those also with CsA/Ara or zVAD, except for the pairs indicated by ‡. Comparisons that
reached statistical significance are shown (**P  0.01). ‡t test was performed between wild-type cells treated with TNF- or anti-Fas in the
presence of CsA/Ara and bid-deficient cells treated with TNF- or anti-Fas only (P values are indicated for A, B, D). ActD, CHX, CsA/Ara, or caspase
inhibitor alone did not cause more significant changes than the controls with vehicle only (data not shown).
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depolarization than CsA/Ara (P  0.05 or  0.01 in
both cases, Figures 5 and 6), it seemed that Bid might
activate a CsA-insensitive mechanism as well.
One possible CsA-insensitive mechanism could be the
oligomerization of the multidomain prodeath molecule,
Bak, as previously indicated on isolated mitochondria.39
Bak is expressed constitutively on the mitochondria and
activated in a Bid-dependent manner during death re-
ceptor-initiated hepatocyte death.18,40 Indeed, cross-link-
ing of the membrane fractions of TNF-– or anti-Fas–
treated hepatocytes indicated that Bak oligomerization
was induced and that this process was not affected by
CsA/Ara treatment (Figure 7).
To differentiate mitochondrial changes resulting from
downstream caspase activation, we examined the effects
of caspase inhibitors in a similar way. An effector caspase
inhibitor, N-acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-
CHO), had little effect on cytochrome c release (Figure
5), but had observable effects on mitochondrial depolar-
ization, particularly in anti-Fas–treated cells (Figure 6).
This suggests that the contribution of the effector
caspases to mitochondrial depolarization was present, but
perhaps independent of cytochrome c release. On the
other hand, a pan-caspase inhibitor, benzyloxy-carbonyl-
Val-Ala-Asp-fluomethylketone (z-VAD-fmk), could al-
most completely inhibit cytochrome c release and mem-
brane depolarization (Figures 5 and 6). This was likely
Figure 7. Bid-induced Bak oligomerization is not affected by CsA/Ara
treatment. Wild-type hepatocytes were treated with (A) TNF-/ActD or
(B) anti-Fas/CHX in the presence or absence of CsA/Ara for 6–8
hours and then harvested. The membrane fraction was isolated and
cross-linked with Dithiobis succinimidylpropionate (DSP, lanes 2–4)
or with the solvent dimethyl sulfoxide alone (DMSO, lane 1) as de-
scribed in the Materials and Methods section. The proteins were then
separated on 12% SDS-PAGE and immunoblotted with the anti-Bak
antibody. Arrows indicate the monomer and dimer form of Bak, which
run at the position of 27 kilodaltons and 54 kilodaltons, respectively.
Data shown represent 4 experiments performed.
Figure 6. Differential effects of PT and caspase inhibitors on mito-
chondrial depolarization. ( ) Wild-type or () bid-deficient hepatocytes
were treated with (A) TNF-/ActD or (B) anti-Fas/CHX for 8 hours.
Other chemicals were added as indicated in Figure 5 legend. Controls
are vehicle only. TMRM (0.5 mol/L) was added at the end of the
culture for 30 minutes. Depolarized cells were quantified and the
number was expressed as the percentage of total cells (polarized and
depolarized, based on phase-contrast observation) (mean  SD).
Statistical analysis was performed with a t test between (A) TNF-– or
(B) anti-Fas–treated groups and other treatment groups for wild-type
hepatocytes except for the pair indicated by ‡ is indicated. Compari-
sons that reached statistical significance are shown (**P  0.01;
*P  0.05). ‡A t test was performed between wild-type cells treated
with (A) TNF- or (B) anti-Fas in the presence of CsA/Ara and bid-
deficient cells treated with TNF- or anti-Fas only (P value is indicated).
ActD, CHX, CsA/Ara, or caspase inhibitor alone did not cause more
significant changes than the controls with vehicle only (data not
shown).
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due to a combined suppression of both downstream
effector caspases and the upstream caspase-8, which
would lead to the suppression of Bid activation in this
system. In summary, these data suggest that mitochon-
drial depolarization could be induced, to a larger extent,
by Bid’s effect on mitochondria (directly or indirectly via
other molecules), and to a lesser extent, by a feedback
effect of effector caspases. On the other hand, cytochrome
c release was dependent mainly on the activity of the
initiator caspase, caspase-8, and Bid. The effect of z-
VAD-fmk on mitochondria activation was equivalent to
that of bid deficiency, but was more significant than that
of CsA/Ara, further suggesting that not all of the Bid
effects were mediated by the CsA/Ara-sensitive mecha-
nism.
Caspase Inhibitors Are More Effective Than
PT Inhibitors in Suppressing Terminal
Apoptotic Events in Anti-Fas–/TNF-
Treated Hepatocytes In Vitro
When the effects of caspase and PT inhibitors on
parameters of the terminal apoptotic changes, such as
caspase activation, nuclear fragmentation/condensation
(Figure 8), and viability (data not shown) were analyzed,
a different pattern was observed. Both z-VAD-fmk and
DEVD-CHO were very effective in suppressing the ter-
minal apoptotic changes, likely because these were me-
diated mainly by the effector caspases. Loss of the bid
gene also provided significant protection, although to a
lesser degree compared with the caspase inhibitors.
Caspase inhibitors could provide further protection in
bid-deficient cells (Figure 8A and B), perhaps by inhib-
iting caspase activation independently of Bid (Figure
8C ). Interestingly, CsA/Ara provided less protection
than bid deficiency (Figure 8A ). Protection by CsA alone
was minimal, and by bongkrakic acid, another PT in-
hibitor, was not observed at all (data not shown). Death
in the presence of CsA/Ara was still apoptotic as deter-
mined by the nuclear staining and also by the effective
suppression by the caspase inhibitors (Figure 8). One
possible explanation for the dissociation between the
inhibitory effects of CsA/Ara on the mitochondrial events
and the end-stage apoptotic events is the presence of the
CsA-/Ara-insensitive killing mechanism, and/or the mi-
Š
Figure 8. Differential effects of PT and caspase inhibitors on cell
viability. ( ) Wild-type or () bid-deficient hepatocytes were treated
with (A, C) TNF-/ActD or (B, C) anti-Fas/CHX for 8 hours. Other
chemicals were added as indicated in Figure 5 legend. (A, B) Controls
are vehicle only. At the end of the culture, cells were fixed and stained
with Hoechst 33342. Cells with apoptotic nuclei (i.e., fragmented or
condensed) (see Figure 1), were quantified. The numbers are ex-
pressed as the percentage of total cells with nuclear staining
(mean  SD). (C) Alternatively, cytosolic fractions were prepared and
analyzed for caspase-3 activities. Statistic analysis was performed
between (A) TNF- or (B) anti-Fas treatment groups and all other
treatment groups for ( ) wild-type and () bid-deficient. (C) Compar-
isons were made between TNF-– or anti-Fas–treated groups alone
and those also with CsA/Ara or zVAD. Only comparisons that reached
significance are shown (*P  0.05; **P  0.01). The difference
between wild-type and bid-deficient cells after TNF- or anti-Fas treat-
ment alone also was significant (P  0.05 and 0.01, respectively).
ActD, CHX, CsA/Ara, or caspase inhibitor alone did not cause more
significant changes than the controls with vehicle only (data not
shown).
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tochondria-independent or Bid-independent killing
mechanism (see Discussion section later). This is con-
firmed by the significant presence of residual effector
caspase activities in CsA-/Ara-treated cells (Figure 8C ).
Thus, these data were consistent with other observations
and suggest that the CsA-/Ara-sensitive mechanism me-
diates only a part, although a larger part, of the effects of
Bid, and that Bid-mediated apoptosis is only a part,
although a larger part, of the cell death programs in-
duced by anti-Fas or TNF- in the cultured primary
hepatocytes (Figure 9).
Discussion
A number of studies on death receptor–induced
hepatocyte apoptosis have been conducted, but some of
the key questions remained unanswered, particularly
those about mitochondria activation. Because the analy-
sis can be performed in a proper cellular environment,
the cell culture system provides a unique way to examine
these issues, which may not be readily addressable by the
animal studies or the in vitro reconstitution analysis. We
thus aimed to determine the mechanism of mitochondria
activation in cultured murine primary hepatocytes after
TNF- or anti-Fas antibody treatment.
We found that bid-deficient hepatocytes had signifi-
cant protection against TNF- or anti-Fas, compared
with the wild-type cells. However, these cells eventually
died from the same stimulation. Thus, the death was
delayed but not prevented by the loss of the bid gene in
this culture system. The death was apoptotic, rather than
necrotic, and the Bid-independent mechanisms, similar
to the Bid-dependent mechanism, were likely mediated
by caspases because z-VAD-fmk protected both wild-
type and bid-deficient cells very well. Although yet to be
defined thoroughly, the potential Bid-independent
mechanisms may include a direct activation of caspase-3
by caspase-8,14,41,42 the activation of the ASK-1/JNK
pathway,43,44 and the activation of RAIDD-caspase-2
pathway.45,46 However, in cultured hepatocytes, the Bid-
dependent pathway was the predominant mechanism for
caspase activation because caspase activities were reduced
significantly in bid-deficient cells after stimulation. One
reason that the Bid-independent killing is more evident
in cultured cells than in animals12,13,40 could be the less
favorable culture condition, which may exacerbate Bid-
independent caspase activation, but not be the use of
ActD or CHX, because the same phenomenon was ob-
served with a more specific nuclear factor B inhibitor, a
nondegradable I-B mutant9 (data not shown). Although
ActD or CHX would be a less favorable chemical than
Figure 9. Schematic representation of Bid-mediated mitochondrial
events in cultured hepatocytes stimulated with anti-Fas or TNF-.
The activation of death receptors, Fas or TNF-R1, by anti-Fas or
TNF-, respectively, can activate an initiator caspase, caspase-8,
which in turn activates effector caspases by a Bid-dependent (1)
and a Bid-independent (2) mechanism. Bid may activate both a (A )
CsA-sensitive mechanism, which CsA can suppress, and a (B)
CsA-insensitive mechanism, which CsA cannot suppress. Both
mechanisms can lead to cytochrome c release and membrane
depolarization. Based on the use of CsA and Ara, it seems that
the CsA-sensitive mechanism may contribute more significantly
to cytochrome c release, as represented by a thicker arrow. The
nature of CsA-sensitive and -insensitive mechanisms is subject
to debate, although PT is one likely candidate for the CsA-sensitive
mechanism. On the other hand, CsA-insensitive mechanisms
may be related to oligomerization of Bak and/or Bax. Mitochon-
dria depolarization (m2) in vivo is caused mainly by the direct
effect of Bid, resulting from events upstream and/or downstream
of cytochrome c release. Depolarization can also be in part caused
by effector caspases through a feedback mechanism (represented
by the dotted arrow). The pan-caspase inhibitor, z-VAD-fmk, pro-
vides the best protection because it inhibits both Bid-dependent
and Bid-independent pathways. The effector caspase inhibitor,
DEVD-CHO, is quite effective in suppressing cell death, but inef-
fective in suppressing the mitochondrial apoptotic events. In con-
trast, bid deficiency or CsA/Ara provides better protection against
the mitochondrial events than the terminal apoptotic changes
because the latter could also be caused by the Bid-independent
mechanism.
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the I-B mutant for sensitizing cells owing to potential
nonspecific toxicity, this has not become a concern in the
current system, for a short incubation period (24 h)
and low doses of chemicals were used.
Nevertheless, the dominance of the Bid pathway and
the dependency of cytochrome c release on Bid found in
the stimulated hepatocytes indicated that the culture
system was an appropriate one to analyze the mechanism
of the Bid-dependent pathway at the level of mitochon-
dria. How Bid induces cytochrome c release is not well
understood, although studies primarily based on in vitro
reconstitution systems indicate that the mitochondrial
outer membranes remain intact during the process, with
little mitochondrial swelling17,18 and membrane depo-
larization.17,19 In contrast, Bid requires Bak or Bax to
release cytochrome c,15,18,40 which could form special
transmembrane channels on the outer membranes.35
Thus, it seems that the role of PT pore in cytochrome c
release, the activation of which was traditionally charac-
terized by mitochondrial swelling and outer membrane
disruption, was not readily shown.
Paradoxically, studies using primary hepatocyte cul-
ture found that cytochrome c release induced by anti-Fas
or TNF- could be suppressed by CsA alone8 or in
combination with trifluoperazine,9 both are classic inhib-
itors of the PT pore. These studies thus suggest that the
pore could be involved in cytochrome c release in cells.
Moreover, because Bid is required for cytochrome c re-
lease in this system (Figure 3), it could be inferred that
Bid might activate PT, which CsA can inhibit. Indeed,
we found that CsA in combination with Ara, another
enhancing agent for CsA,21,47,48 could suppress cyto-
chrome c release in anti-Fas or TNF-–treated wild-type
hepatocytes. However, this inhibition was less significant
than that caused by bid deletion. The differences between
the 2 conditions were small and varied in experiments,
but were consistently observable and statistically signif-
icant (P  0.01 and 0.03 for TNF- and anti-Fas
treatment, respectively). These data suggest that Bid can
trigger a CsA-sensitive mechanism and a less-dominant
CsA-insensitive mechanism for the release of cytochrome
c. Alternatively, a CsA-insensitive unregulated PT pore
may become involved in part.37 It has to be pointed out
that the effects of CsA do not seem to be mediated by its
inhibition on calcineurin, a serine-threonine phospha-
tase, because a more specific calcineurin inhibitor,
FK506, does not have the same effects as CsA on mito-
chondria activation.49,50
It had been difficult to reconcile the cellular studies
with the in vitro reconstitution studies. However, a
recent study re-examined some of the issues using the in
vitro system and found that cytochrome c release induced
by Bid could be mediated by 2 different mechanisms.39
One was responsible for the initial release of free cyto-
chrome c present in the intermembrane space through a
Bak-dependent mechanism. The other caused a dramatic
remodeling of mitochondrial cristae, which mobilized
the cytochrome c storage. This portion of cytochrome c
constituted the majority (85%) of the total released.
Interestingly, the latter event could be suppressed by
CsA. Our observations with the cellular system are con-
sistent with this study in that distinguishable mecha-
nisms of cytochrome c release could be discerned based on
CsA sensitivity and the CsA-sensitive mechanism seems
to be the major one.
The CsA-insensitive mechanism could be attributed to
outer membrane permeabilization mediated by Bid-acti-
vated Bak or Bax oligomerization, which is important for
the initial release of a smaller amount of cytochrome
c.18,39,40 Our study supports this notion because CsA/Ara
could not suppress Bak oligomerization in the cultured
hepatocytes stimulated with TNF- or anti-Fas (Figure
7) and indicates that at least Bak oligomerization could
serve as a CsA-insensitive mechanism. But the nature of
the CsA-sensitive or CsA-suppressible mechanism re-
mains elusive. Cellular studies indicate that this mech-
anism may be considered as PT because CsA is a classic
inhibitor of it, which acts on mitochondrial cyclophilin
D.8,9,20,28,38 To some extent, the CsA-insensitive mech-
anism also may be considered to be related to PT because
it has been suggested that one conductance mode of PT
is CsA unregulated.37 However, the fact that most mi-
tochondria remain intact without swelling after treat-
ment with truncated Bid in vitro16–19,39 suggests that if
PT is indeed induced by Bid, it probably does not stand
in open mode, but rather flickers or rapidly cycles
through an open and closed status.37,38 This, however,
will still allow the nonspecific redistribution of small
molecular weight solutes, such as Calcein AM, across the
mitochondria.8,9,28,38 It is not clear how this mode of PT
will then cause cytochrome c release without disrupting
the mitochondria outer membrane. It is therefore possi-
ble that the Bid-activated CsA-sensitive mechanism can
also represent other mitochondrial targets that CsA can
affect, such as the mitochondrial cristae whose remodel-
ing can lead to the mobilization of stored cytochrome c.39
A change parallel to the redistribution of Calcein AM
is mitochondria depolarization, which was also observed
in hepatocytes after death receptor activation. No signif-
icant mitochondrial depolarization was observed in re-
combinant tBid-treated mitochondria in vitro.17,19,39
However, studies based on many cellular systems often
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found that depolarization was accompanied by cyto-
chrome c release,35,51,52 although the mechanisms could
be quite diverse. One possible mechanism is that addi-
tional factors may be required for depolarization to occur
in a scale large enough to be detected. Caspases could be
one of the factors in the cell.52 Both z-VAD-fmk and
DEVD-CHO could suppress mitochondrial depolariza-
tion in anti-Fas– or TNF-–treated hepatocytes. One
may not be able to separate the inhibitory effect of
z-VAD-fmk on Bid activation (via caspase-8 inhibition)
from that on effector caspases. However, the partial
inhibition of depolarization by DEVD-CHO in treated
hepatocytes indicates that at least some of the depolar-
ization events could be attributed to the effects of effector
caspases. Thus, a direct in vivo effect of Bid, alone or in
combination with other factors, on mitochondrial poten-
tials is possible. In this scenario, depolarization may not
result from a massive outer membrane disruption, but
from the flickering of the PT pore and/or the massive
release of cytochrome c after the activation of the CsA-
sensitive mechanism. This may explain why depolariza-
tion was also sensitive to CsA suppression to a large
extent. Because the release of total cytochrome c can be
completed in minutes,52 it probably would not be sur-
prising that Calcein AM redistribution, cytochrome c
mobilization, and membrane depolarization were kinet-
ically inseparable under the current observation conditions.
In conclusion, our data support the model that a
Bid-mediated mitochondria pathway is a dominant ap-
optosis pathway in hepatocytes after death receptor acti-
vation and that Bid can activate a CsA-sensitive pathway
in addition to a CsA-insensitive pathway to induce mi-
tochondrial release of cytochrome c (Figure 9). These
mechanisms may also be operative in other types of cells
undergoing mitochondria-dependent apoptosis initiated
by other death stimuli.
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